Roth/MKM analyst Boobalan Pachaiyappan reiterated a Buy rating and $31.00 price target on Capricor Therapeutics (NASDAQ: CAPR)The analyst comments "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE